exendin-4 peptide exendin-4 (Ex4 - Exenatide a 39-amino acid peptide fragment Exendin-4 Peptide: A Deep Dive into its Discovery, Mechanism, and Therapeutic Potential

Glucagon likepeptide1 receptor mechanisms and advances in therapy Exendin-4 peptide is a fascinating molecule with significant implications in the realm of diabetes research and treatmentExendin-4 Recombinant isa novel 39-amino acids peptidehaving a molecular mass of 4186.7 Dalton, which shares 53%, sequence homology with GLP-17-36 amide.. Originally discovered in the saliva of the Gila monster (*Heloderma suspectum*), this biologically active polypeptide has garnered considerable attention due to its striking similarity to human incretin hormones and its potent effects on glucose regulationThis peptide isfound in the venom of the Gila monster Heloderma suspectum. Exenatide is the synthetic form of the peptide used in clinical practice.. This article will delve into the intricate details of exendin-4, exploring its structure, its biological functions, its therapeutic applications, and its ongoing scientific exploration.[Cys]-Exendin 4 | CRB1000606

The Genesis of Exendin-4: From Gila Monster Venom to Therapeutic Promise

The story of exendin-4 begins with the venom of the Gila monster. This remarkable reptile, native to the southwestern United States and northwestern Mexico, possesses a venom that contains unique peptides with pharmacological properties. A key component of this venom is exendin-4, a 39 amino acid peptide that was first isolated and characterized in the early 1990s. Subsequent research revealed that exendin-4 is a peptide agonist of the glucagon-like peptide (GLP) receptor. This discovery was pivotal, as it identified exendin-4 as a potent mimic of the naturally occurring human hormone, glucagon-like peptide-1 (GLP-1).

Understanding the Molecular Architecture: Exendin-4 Structure and Sequence

At its core, exendin-4 is a 39-amino acid peptide amideExendin-4 | Glucagon-Like Peptide 1 Receptor Agonists. Its precise chemical formula is often cited as C184H282N50O60S. While it shares structural similarities with GLP-1, exendin-4 exhibits distinct characteristics that contribute to its therapeutic advantagesExendin-4 is a 39-amino acid peptide amide. Exendin-4, like Exendin-3, stimulates an increase in acinar cAMP without stimulating the release of amylase.. The exendin-4 sequence has been extensively studied, and it demonstrates approximately 50% sequence homology with GLP-1(7-36)-amide. This homology allows exendin-4 to bind effectively to the glucagon-like peptide 1 receptor (GLP-1R), a key player in glucose homeostasis.

Researchers have explored various exendin-4 peptide analogues with the goal of optimizing its therapeutic profileExendin-4 (Exenatide，艾塞那肽) - 仅供科研. These modifications can influence factors such as receptor binding affinity, metabolic stability, and duration of action.Exendin-4 (Exenatide)是由39 个氨基酸组成的多肽。它是长效的glucagon-like peptide-1 受体激动剂，IC50 值为3.22 nM。- 高纯度，全球文献引用。 The development of exendin-4 (Ex4) derivatives, including exendin-4 (3-39) which functions as a potent GLP-1 receptor antagonist, highlights the ongoing efforts to understand and manipulate its interactions with the GLP-1 receptor system.Exendin 4 (3-39)

The Mechanism of Action: Mimicking GLP-1 for Enhanced Glucose Control

Exendin-4's therapeutic efficacy stems from its ability to mimic and amplify the actions of GLP-1. As an agonist of the glucagon-like peptide 1 receptor, exendin-4 plays a crucial role in regulating blood glucose levels through several mechanisms:

* Stimulation of Insulin Secretion: Like GLP-1, exendin-4 binds to GLP-1 receptors on pancreatic beta cells, stimulating the release of insulin in a glucose-dependent mannerDiabetes drug from Gila monster venom - VA Research. This means that insulin secretion is enhanced when blood glucose levels are high, minimizing the risk of hypoglycemia. This property is critical for the management of type 2 diabetes.

* Suppression of Glucagon Secretion: Exendin-4 also acts on pancreatic alpha cells to suppress the secretion of glucagon, a hormone that raises blood glucose levels.Exendin-4is a high affinity glucagon-like peptide 1 (GLP-1) receptor agonist(K d = 136 pM); originally isolated from Heloderma suspectum venom. By reducing glucagon output, exendin-4 further contributes to lowering overall glycemic levels.

* Delayed Gastric Emptying: Exendin-4 can slow down the rate at which food leaves the stomach. This leads to a more gradual absorption of carbohydrates from the intestines, contributing to a reduction in postprandial (after-meal) blood glucose spikes.Diabetes drug from Gila monster venom - VA Research

* Increased Satiety: The delayed gastric emptying and effects on the central nervous system can also contribute to increased feelings of fullness, potentially aiding in weight management for individuals with diabetes作者：M Wolff·2020·被引用次数：12—Glucagon-like peptide-1 (GLP-1) andexendin-4 (Ex4) are homologous peptides with established potential for treatment of type 2 diabetes. They bind and activate ....

The binding affinity of exendin-4 to the GLP-1 receptor is notably high, with reported Kd values as low as 136 pM.作者：JW Neidigh·2001·被引用次数：300—Exendin-4 ( 6) is a 39 amino acid peptidethat exhibits several of the antidiabetic actions of the mammalian hormone GLP-1. Exendin-4 displays approximately 50% ... This high affinity contributes to its potent agonist activity.

Therapeutic Applications and the Rise of Exenatide

The potent biological activity of exendin-4 has led to its development into pharmaceutical drugs. Exenatide, the synthetic form of exendin-4, is a well-established medication for the treatment of type 2 diabetes mellitus.Venom protein that mimics the incretin hormone glucagon-like peptide 1 (GLP-1). It stimulates insulin synthesis and secretion, protects against beta-cell ... It is administered as an injectable long-acting glucagon-like peptide-1 receptor agonist.Isolation and Characterization of Exendin-4, an ... Exenatide has demonstrated significant success in improving glycemic control, with efficacy often measured by metrics such as HbA1c levels.

Unlike native GLP-1, which is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), exendin-4 exhibits greater resistance to enzymatic degradation. This results in a longer duration of action, allowing for less frequent dosing and improved patient adherence. While the exact factors contributing to its increased metabolic stability are still an area of research, this characteristic is a key advantage of exendin-4-based therapies作者：G Graham·2020·被引用次数：13—Dive into the research topics of 'Role ofexendin-4in the Gila monster: Further lessons regarding human oral glucagon-likepeptide-1 therapy?'..

Beyond Diabetes: Exploring New Frontiers for Exendin-4

The therapeutic potential of exendin-4 extends beyond diabetesExendin 4 - an overview. Emerging research suggests its involvement in other physiological processes and potential applications in various disease states. Studies have explored the anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on peripheral lymphocytes in patients with type 2 diabetes. Furthermore, exciting research is investigating the role of exendin-4 in neurodegenerative conditions, with some studies exploring its potential in treatments for Alzheimer's diseaseExendin-4.

The discovery of exendin-4 has opened up a significant avenue for understanding incretin-based therapies and developing novel treatments for metabolic and potentially other diseases.2012年7月11日—A component of the Gila monster's venom—a peptide known as exendin-4—is being explored for new treatments for Alzheimer's disease, diabetes, and other diseases. The ongoing research into Exendin-4 structure, GLP1 sequence, and Glucagon like peptide 1 receptor mechanisms and advances in therapy continues to unravel the full potential of this remarkable peptide derived from an unexpected source. The development of Peptides like exendin-4 represents a significant advancement in medicinal chemistry and pharmacology, offering hope for improved patient outcomes in various therapeutic areas.